Tumor physiologic response to combretastatin A4 phosphate assessed by MRI

International Journal of Radiation Oncology Biology Physics

Volumn 62, Issue 3, 2005, Pages 872-880

  Zhao, Dawen ^a   Jiang, Lan ^a   Hahn, Eric W ^a   Mason, Ralph P ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Breast tumor; MRI; Oxygenation; Vascular targeting agent; Vasculature

Indexed keywords

MAGNETIC RESONANCE IMAGING; MECHANICAL PERMEABILITY; PHOSPHATES; PHYSIOLOGY; RADIOTHERAPY;

PERFUSION; TUMOR OXYGENATION; VASCULAR TARGETING AGENT;

TUMORS;

COMBRETASTATIN A4 PHOSPHATE; CONTRAST MEDIUM;

ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPOXIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIMETRY; OXYGEN TENSION; OXYGENATION; PERFUSION; PRIORITY JOURNAL; RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL HYPOXIA; FEMALE; FLUORINE; MAGNETIC RESONANCE IMAGING; MAMMARY NEOPLASMS, ANIMAL; OXIMETRY; OXYGEN; OXYGEN CONSUMPTION; PARTIAL PRESSURE; RATS; RATS, INBRED F344; REGIONAL BLOOD FLOW; STILBENES;

EID: 20344378675     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.03.009     Document Type: Article

References (41)

1. J. Folkman Anti-angiogenesis New concept for therapy of solid tumors Ann Surg 175 1972 409 416
2. J. Denekamp Vascular attack as a therapeutic strategy for cancer Cancer Metastasis Rev 9 1990 267 282
3. G.R. Pettit, C. Temple Jr, V.L. Narayanan Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs Anticancer Drug Des 10 1995 299 309
4. P.D. Davis, G.J. Dougherty, D.C. Blakey ZD6126 A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res 62 2002 7247 7253
5. G.G. Dark, S.A. Hill, V.E. Prise Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res 57 1997 1829 1834
6. D.W. Siemann, K.H. Warrington, M.R. Horsman Targeting tumor blood vessels An adjuvant strategy for radiation therapy Radiother Oncol 57 2000 5 12
7. P.E. Thorpe, D.J. Chaplin, D.C. Blakey The first international conference on vascular targeting Meeting overview Cancer Res 63 2003 1144 1147
8. D.W. Siemann, A.M. Rojiani Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 53 2002 164 171
9. R. Murata, D.W. Siemann, J. Overgaard Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors Radiother Oncol 60 2001 155 161
10. R. Murata, D.W. Siemann, J. Overgaard Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4- acetic acid Radiat Res 156 2001 503 509
11. L. Li, A.M. Rojiani, D.W. Siemann Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma Acta Oncol 41 2002 91 97
12. D.W. Siemann, A.M. Rojiani Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 54 2002 1512 1517
13. G.M. Tozer, V.E. Prise, J. Wilson Combretastatin A-4 phosphate as a tumor vascular-targeting agent Early effects in tumors and normal tissues Cancer Res 59 1999 1626 1634
14. M. Kragh, B. Quistorff, M.R. Horsman Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy Neoplasia 4 2002 263 267
15. D.E. Goertz, J.L. Yu, R.S. Kerbel High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow Cancer Res 62 2002 6371 6375
16. G.J. Rustin, S.M. Galbraith, H. Anderson Phase I clinical trial of weekly combretastatin A4 phosphate Clinical and pharmacokinetic results J Clin Oncol 21 2003 2815 2822
17. S.M. Galbraith, R.J. Maxwell, M.A. Lodge Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol 21 2003 2831 2842
18. V.E. Prise, D.J. Honess, M.R. Stratford The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses Int J Oncol 21 2002 717 726
19. S.P. Robinson, D.J. McIntyre, D. Checkley Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging Br J Cancer 88 2003 1592 1597
20. D.J. McIntyre, S.P. Robinson, F.A. Howe Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model Neoplasia 6 2004 150 157
21. A.R. Padhani MRI for assessing antivascular cancer treatments Br J Radiol 76 Spec No 1 2003 S60 S80
22. M.R. Horsman, E. Ehrnrooth, M. Ladekarl The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors Int J Radiat Oncol Biol Phys 42 1998 895 898
23. M.R. Horsman, R. Murata Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response Int J Radiat Oncol Biol Phys 57 2003 1047 1055
24. S. Hunjan, D. Zhao, A. Constantinescu Tumor oximetry Demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor Int J Radiat Oncol Biol Phys 49 2001 1097 1108
25. D. Zhao, L. Jiang, R.P. Mason Measuring changes in tumor oxygenation Methods Enzymol 386 2004 378 418
26. D. Zhao, A. Constantinescu, E.W. Hahn Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge Int J Radiat Oncol Biol Phys 53 2002 744 756
27. D. Zhao, A. Constantinescu, E.W. Hahn Tumor oxygen dynamics with respect to growth and respiratory challenge Investigation of the Dunning prostate R3327-HI tumor Radiat Res 156 2001 510 520
28. R.P. Mason, S. Ran, P.E. Thorpe Quantitative assessment of tumor oxygen dynamics Molecular imaging for prognostic radiology J Cell Biochem 87 2002 45 53
29. E.W. Hahn, P. Peschke, R.P. Mason Isolated tumor growth in a surgically formed skin pedicle in the rat A new tumor model for NMR studies Magn Reson Imaging 11 1993 1007 1017
30. R.B. Pedley, S.A. Hill, G.M. Boxer Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate Cancer Res 61 2001 4716 4722
31. 19F MR EPI and frequency domain NIR spectroscopy Adv Exp Med Biol 530 2003 225 236
32. Y. Song, A. Constantinescu, R.P. Mason Dynamic breast tumor oximetry The development of prognostic radiology Technol Cancer Res Treat 1 2002 1 8
33. J.M. Brown The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain memorial award lecture Cancer Res 59 1999 5863 5870
34. M. Höckel, K. Schlenger, B. Aral Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
35. D.M. Brizel, S.P. Scully, J.M. Harrelson Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 1996 941 943
36. M. Höckel, P. Vaupel Tumor hypoxia Definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266 276
37. 2) inside tumors? Magn Reson Med 48 2002 980 986
38. 19F MRI [Abstract] Proc Int Soc Magn Reson Med 1 2004 222
39. D.A. Beauregard, R.B. Pedley, S.A. Hill Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS NMR Biomed 15 2002 99 105
40. 19F PBSR EPI of hexafluorobenzene Magn Reson Imaging 15 1997 971 981
41. 19F NMR indicator of tumor oxygenation NMR Biomed 9 1996 125 134